Clinical trials in rare lymphomas

The table below shows a list of The Lymphoma Group's current clinical trials open for recruitment for rare lymphomas such as:

  • Mantle cell lymphoma
  • Burkitt's lymphoma
  • MALToma (Marginal zone) lymphoma
  • CNS (brain) lymphoma
  • Waldenström macroglobulinemia

If you would like to know how to access our trials please click here


Trial name




Click for more information (external page)




Phase 1/2 study using antibody GEN3013 to target CD20- expressing cells in patients with B cell non Hodgkin lymphoma

Suitable for patients with mantle cell, marginal zone and other B cell Non Hodgkin lymphomas







Phase 2 study determining efficacy and safety of JCAR017.

Suitable for patients with PCNSL, CNS involved lymphoma, Richter's transformation, and DLBCL which has come back after previous treatment






A phase 1/1b trial testing mosunetuzumab, on its own or with atezolizumab.

Suitable for patients with lymphoma which has come back after previous treatment






A randomised, phase 2/3 trial comparing ibrutinib plus rituximab with standard treatment in people with Waldenström’s macroglobulinaemia.






A phase 2 trial of rituximab and pembrolizumab in people with relapsed or refractory Waldenström’s macroglobulinaemia.






A phase 3 trial of zanubrutinib plus rituximab in older people with untreated mantle cell lymphoma.



With special thanks to the following:

Last updated: October 2021